Trump Announces New Drug Pricing Agreements With Nine Pharma Companies
President Donald Trump has announced new drug pricing agreements with nine pharmaceutical companies, bringing the total number of such deals to 26. The agreements aim to align U.S. drug prices more closely with international rates by requiring discounts on outpatient drugs in state Medicaid programs. Participating firms include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals Industries Ltd., and UCB. The companies have also committed to investing $19.6 billion collectively into U.S. manufacturing in the near term. Additionally, some firms like Astellas, Sun Pharma, Teva, and UCB will donate active pharmaceutical ingredients (API) for key medicines to a federal strategic reserve. The Trump administration claims these 26 companies represent 90% of the domestic pharmaceutical market. The agreements are part of the
Topics: government_policy healthcare international_comparisons pharmaceuticals